PROCEPT BioRobotics Adjusts Outlook Amid Shift in System Replacement Forecasts
ByAinvest
Thursday, Aug 21, 2025 11:20 am ET1min read
PRCT--
ProCEPT BioRobotics Corporation (NASDAQ:PRCT), a leader in urology surgical robotics, has revised its system replacement forecasts. Wells Fargo, an investment research firm, has maintained its Overweight rating on the company but reduced its price target from $75 to $58 [1]. The change comes following management's announcement that it no longer anticipates any system replacements in the second half of 2025, reversing earlier projections of roughly 10 replacements this year.
The AquaBeam Robotic System, PROCEPT's flagship product, is a cutting-edge image-guided device intended for minimally invasive urologic procedures. The system's single-use disposable handpiece provides recurring business growth for the company. PROCEPT's total addressable market (TAM) for BPH-related diseases is estimated to reach $20 billion in the U.S. market [2].
Wells Fargo pointed out that PROCEPT's installed base, which is primarily three years old, has overstated the need for replacements, even though the company forecasts system life to be five to seven years. The firm currently projects 10 replacements at an average selling price of $350,000 for 2026 and expects PROCEPT management to discuss its replacements and trade-in strategy when delivering guidance for the upcoming year [1].
The company reported its Q2 FY25 results on August 6, posting 48% growth in revenue and a 20% increase in its U.S. system install base. The company exited the quarter with $306 million in cash and $52 million in total debts [2]. PROCEPT anticipates achieving break-even by FY27, driven by 30% revenue growth, 5% price improvements, and 25% growth from system and disposable handpiece sales [2].
Key risks include competition from traditional TURP procedures and laser-based therapies, as well as the need to expand its sales force and engage with more surgeons in target hospitals. PROCEPT aims to target 2,700 hospitals that perform respective BPH procedures in the U.S. market [2].
References
[1] https://ca.finance.yahoo.com/news/procept-biorobotics-prct-outlook-adjusted-151509614.html
[2] https://seekingalpha.com/article/4813845-procept-biorobotics-increasing-average-selling-price-initiate-at-buy
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has revised its system replacement forecasts, with Wells Fargo maintaining an Overweight rating and reducing the price target from $75 to $58. The company no longer expects any system replacements in H2 2025, reversing earlier projections of 10 replacements. The AquaBeam Robotic System is a flagship product for minimally invasive urologic procedures.
Title: PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Adjusts System Replacement Forecasts, Maintains Overweight RatingProCEPT BioRobotics Corporation (NASDAQ:PRCT), a leader in urology surgical robotics, has revised its system replacement forecasts. Wells Fargo, an investment research firm, has maintained its Overweight rating on the company but reduced its price target from $75 to $58 [1]. The change comes following management's announcement that it no longer anticipates any system replacements in the second half of 2025, reversing earlier projections of roughly 10 replacements this year.
The AquaBeam Robotic System, PROCEPT's flagship product, is a cutting-edge image-guided device intended for minimally invasive urologic procedures. The system's single-use disposable handpiece provides recurring business growth for the company. PROCEPT's total addressable market (TAM) for BPH-related diseases is estimated to reach $20 billion in the U.S. market [2].
Wells Fargo pointed out that PROCEPT's installed base, which is primarily three years old, has overstated the need for replacements, even though the company forecasts system life to be five to seven years. The firm currently projects 10 replacements at an average selling price of $350,000 for 2026 and expects PROCEPT management to discuss its replacements and trade-in strategy when delivering guidance for the upcoming year [1].
The company reported its Q2 FY25 results on August 6, posting 48% growth in revenue and a 20% increase in its U.S. system install base. The company exited the quarter with $306 million in cash and $52 million in total debts [2]. PROCEPT anticipates achieving break-even by FY27, driven by 30% revenue growth, 5% price improvements, and 25% growth from system and disposable handpiece sales [2].
Key risks include competition from traditional TURP procedures and laser-based therapies, as well as the need to expand its sales force and engage with more surgeons in target hospitals. PROCEPT aims to target 2,700 hospitals that perform respective BPH procedures in the U.S. market [2].
References
[1] https://ca.finance.yahoo.com/news/procept-biorobotics-prct-outlook-adjusted-151509614.html
[2] https://seekingalpha.com/article/4813845-procept-biorobotics-increasing-average-selling-price-initiate-at-buy
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet